LEADER 01270nas 2200469- 450 001 9910679259703321 005 20240111213018.0 011 $a2334-1203 035 $a(OCoLC)871686356 035 $a(CKB)2670000000555385 035 $a(CONSER)--2014201580 035 $a(EXLCZ)992670000000555385 100 $a20140307a20149999 --- a 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCraft beer & brewing 210 1$aFort Collins, CO :$cUnfiltered Media Group, LLC,$d2014- 311 $a2334-119X 517 1 $aCraft beer & brewing magazine 517 1 $aCraft beer and brewing 531 0 $aCraft beer brew. 606 $aBeer 606 $aBeer industry 606 $aBrewing 606 $aBeer$2fast$3(OCoLC)fst00829736 606 $aBeer industry$2fast$3(OCoLC)fst00829764 606 $aBrewing$2fast$3(OCoLC)fst00838522 608 $aPeriodicals.$2fast 615 0$aBeer. 615 0$aBeer industry. 615 0$aBrewing. 615 7$aBeer 615 7$aBeer industry 615 7$aBrewing. 676 $a641.873 906 $aJOURNAL 912 $a9910679259703321 996 $aCraft beer & brewing$93081527 997 $aUNINA LEADER 05887nam 2201453z- 450 001 9910595078903321 005 20220916 035 $a(CKB)5680000000080736 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/92136 035 $a(oapen)doab92136 035 $a(EXLCZ)995680000000080736 100 $a20202209d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aIntraocular Pressure and Ocular Hypertension 210 $aBasel$d2022 215 $a1 online resource (288 p.) 311 08$a3-0365-5100-X 311 08$a3-0365-5099-2 330 $aPrimary open-angle glaucoma (POAG) is a multi-factorial progressive optic neuropathy characterized by retinal ganglion cell degeneration and progressive visual field loss which, if left untreated, may lead to blindness. Increased intraocular pressure (IOP) is considered to be the main risk factor for developing POAG, and its reduction has been shown to correlate with a decrease in glaucoma incidence and progression. Considering that fewer than 10% of the subjects with ocular hypertension (OHT) will develop morphological and/or functional glaucomatous damage within 5 years if not treated, glaucoma causes and molecular changes leading to ocular tissue damage in glaucoma are still largely unknown. The contemporary treatment of POAG is mainly oriented towards reducing IOP; the importance of the IOP reduction in other types of glaucoma, such as the "normal pressure glaucoma", is still discussed. The IOP value is maintained by balancing the amount of fluid contained within the anterior and posterior chambers of the eye; our comprehension of the mechanisms underlying the secretion and active and passive outflow of the aqueous humor is extremely important for improving the treatment of glaucoma. Innovative pharmacological approaches, and laser and surgical procedures aiming to reduce IOP, have been developed in recent years. This book provides a compendium of topics regarding IOP, aqueous humor dynamics, tonometry, and medical and surgical techniques developed to reduce the IOP in subjects with ocular hypertension or glaucoma. 606 $aMedicine$2bicssc 610 $a3D culture 610 $aab interno trabeculotomy 610 $aage 610 $aanti-VEGF agents 610 $aaphakia 610 $aaqueous humor 610 $aBruch's membrane opening-minimum rim width 610 $acanaloplasty 610 $acataract extraction 610 $acataract surgery 610 $acentral corneal thickness 610 $acentral corneal thickness (CCT) 610 $achildhood glaucoma 610 $acorneal biomechanics 610 $acorneal hysteresis 610 $acorneal resistance factor 610 $acorneal thickness 610 $acyclodestruction 610 $acytoskeleton 610 $adropless treatment 610 $aEsnoper V-2000 implant 610 $aextraocular muscle 610 $afemale 610 $aGDF15 610 $aglaucoma 610 $aglaucoma drainage device 610 $aglucocorticoids 610 $aGoldmann Applanation tonometer 610 $aGoldmann applanation tonometer (GAT) 610 $ahigher-order aberrations 610 $aiCare 610 $aiCare tonometry 610 $aincision in the Schlemm's canal in degrees 610 $ainhaled administration 610 $aintranasal administration 610 $aintraocular pressure 610 $aintraocular pressure (IOP) 610 $aintraocular pressure measurement 610 $aintravitreal injection 610 $aIOP fluctuation 610 $aKahook Dual Blade 610 $alaser treatment 610 $alensectomy 610 $amagnetic resonance imaging 610 $amanagement (or therapy) 610 $aMatrigel 610 $aminimally invasive glaucoma surgeries (MIGS) 610 $amyopia 610 $an/a 610 $aneuroretina 610 $aneuroretinal rim reversal 610 $anon-contact tonometer 610 $anon-penetrating deep sclerectomy 610 $anon-perforating surgical procedures 610 $aocular hypertension 610 $aocular response analyzer 610 $aOMNI viscosurgical system 610 $aopen angle glaucoma (OAG) 610 $aopen-angle glaucoma 610 $aORA 610 $aoutflow 610 $aPerkins tonometry 610 $aphase-sensitive optical coherent tomography 610 $apost-surgical complication 610 $aprimary open-angle glaucoma 610 $aprogression 610 $aprostaglandin analog 610 $apseudoexfoliation glaucoma (PEXG) 610 $apseudophakia 610 $apulsatile motion 610 $arebound tonometer 610 $arefractive error 610 $arho-kinase inhibitor 610 $arisk stratification 610 $asafety profile 610 $aSchlemm's canal 610 $aSchlemm's canal viscodilation 610 $aserum 610 $aserum calcium 610 $astandardized anaesthesia 610 $asteroid response 610 $asystemic administration 610 $aT2 relaxation time 610 $athyroid-associated ophthalmopathy 610 $atonometry 610 $atrabecular meshwork 610 $atrabeculectomy 610 $atrabeculotomy 610 $aXEN GelStent 615 7$aMedicine 700 $aBrusini$b Paolo$4edt$01328476 702 $aSalvetat$b Maria Letizia$4edt 702 $aZeppieri$b Marco$4edt 702 $aBrusini$b Paolo$4oth 702 $aSalvetat$b Maria Letizia$4oth 702 $aZeppieri$b Marco$4oth 906 $aBOOK 912 $a9910595078903321 996 $aIntraocular Pressure and Ocular Hypertension$93038588 997 $aUNINA